Accentuating cardiovascular events in Sibutramine-treated patients

2022 ◽  
Vol 71 (12) ◽  
pp. 2852-2852
Author(s):  
Radeyah Waseem ◽  
Mahnoor Raza ◽  
Aleena Aftab

Sibutramine has been used as an anti-obesity drug, sold under the brand name of Meridia, among others. However, it was banned in various countries after a statistically impactful finding that it increases the risk of cardiovascular events even in patients who were not at a predisposed risk. Despite these findings, Sibutramine is still prescribed in Pakistan, in spite of the high prevalence of cardiovascular diseases in our population. In this letter, we have summarized the long-known, and recent findings regarding Sibutramine and have also provided the statistics to empower our reasoning. We believe that this letter will prove to be a valuable asset in spreading awareness regarding Sibutramine within the medical community in Pakistan. Continuous...

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15039-e15039
Author(s):  
Vincenzo Quagliariello ◽  
Simona Buccolo ◽  
Martina Iovine ◽  
Andrea Paccone ◽  
Annamaria Bonelli ◽  
...  

e15039 Background: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapy to treat hypercholesterolaemia and related cardiovascular diseases. Evolocumab, a PCSK9 inhibitor, reduced the risk of cardiovascular events in patients with atherosclerotic cardiovascular diseases when added to maximally tolerated statin therapy (± ezetimibe), and recent data from the ODYSSEY OUTCOMES trial indicate that alirocumab added to maximally tolerated statin therapy (± other lipid-lowering drugs) reduces the risk of cardiovascular events in patients with a recent acute coronary syndrome. Methods: Human fetal cardiomyocytes (HFC cell line), human HER2+ breast cancer cells were exposed to subclinical concentration of doxorubicin, trastuzumab, sequential treatment of both (all 100 nM), alone or in combination with evolocumab (50 nM) for 24 and 48h. After the incubation period, we performed the following tests: determination of cell viability, through analysis of mitochondrial dehydrogenase activity, study of lipid peroxidation (quantifying cellular Malondialdehyde and 4-hydroxynonenal), intracellular Ca2+ homeostasis. Moreover, pro-inflammatory studied were also performed (activation of NLRP3 inflammasome; expression of TLR4/MyD88; mTORC1 Fox01/3a; transcriptional activation of p65/NF-κB and secretion of cytokines involved in cardiotoxicity (Interleukins 1β, 8, 6). Results: Evolocumab co-incubated with doxorubicin alone or in sequence with trastuzumab exerts cardioprotective effects, enhancing cell viability of 35-43% compared to untreated cells (p < 0,05 for all); in cardiomyocytes Evolocumab reduced significantly the cardiotoxicity through MyD88/NF-KB/cytokines axis and mTORC1 Fox01/3α mediated mechanisms. In human HER2+ breast cancer cells, co-exposure of Evolocumab with doxorubicin and trastuzumab increased significantly cell apoptosis and necrosis through the involvement of key cytokines involved in chemoresistence. Conclusions: We demonstrated, for the first time, that the PCSK9 inhibitor evolocumab exerts direct effects in cardiomyocytes and human HER2+ breast cancer cells during doxorubicin and trastuzumab exposure turning on a new light on its possible use in the management of breast cancer therapies.


Healthcare ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1359
Author(s):  
Lei Yang ◽  
Yuping Mao ◽  
Jeroen Jansz

In this study, we focus on the information available in WeChat official accounts about cardiovascular diseases (CVDs), which are a leading cause of death in China. We are particularly interested in information targeting the Chinese Hui minority people, who have a high prevalence of cardiovascular risk factors (CVRFs). Our exploratory research therefore investigates whether and how the articles on WeChat official accounts are targeted at the Hui people. We used a qualitative approach to analyze 108 articles. Two related themes emerged: descriptions of how to live a healthy life; and explanations of CVDs and CVRFs. Traditional Chinese medicine likewise surfaced from the analysis as a specific and unique theme in the Chinese social and cultural context. Despite the high prevalence of CVRFs among the Hui, none of the articles included information tailored to them.


2015 ◽  
Vol 80 (1) ◽  
Author(s):  
Vincenzo Capuano ◽  
Norman Lamaida ◽  
Sergio Torre ◽  
Ernesto Capuano ◽  
Maria Immacolata Borrelli ◽  
...  

Rationale: In Italy the mortality data were obtained almost exclusively from the data RENCAM (Name Causes of Death Register), while there are few prospective surveys. In order to assess whether there are particular epidemiological conditions in the geographical area of Mercato S. Severino, in Southern Italy, we have studied, and reassessed at ten years (1998/99 - 2008/09), a cohort of adult general population in a project of cardiovascular epidemiology and prevention. Materials and Methods: We calculated the rates of mortality and morbidity from cardiovascular events covering the period 1998/99 - 2008/09, in a cohort of 1200 persons (600 men and 600 women) aged 25 to 74 years. Data were standardized using the European standard population. Results: Mortality from cardiovascular causes was 46,5% in men and 48,7% in women; it was mainly concentrated in the age group 65-74 years where it occurred on 62,9% of deaths in men and 66,7% in women. Regarding morbidity, the incidence of events to ten years of non-fatal myocardial infarction was 2,2% in men and of 1,8% in women. PTCA interventions to ten year have been 3,3% in men and 3,4% in women, the interventions of aorto-coronary bypass have been 2,4% and 0,5% for men and women respectively. While all major cardiovascular events have been more frequent in men, in women there was a higher incidence of stroke (1,6% vs 0,9%). Conclusions: Although by comparison with other European countries Italy is among the countries considered at low-risk of coronary heart disease, in Campania cardiovascular diseases reach higher rates than the rest of the country. Our results are in line with the literature data and confirm that cardiovascular diseases are a major public health problem. Local analysis to propose means to provide useful information for planning prevention interventions targeted to their own territory.


BMJ Open ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. e032633 ◽  
Author(s):  
Kuo-Liong Chien ◽  
Ting-Yu Lin ◽  
Chen-Yang Hsu ◽  
Chang-Chuan Chan ◽  
Tony Hsiu-Hsi Chen ◽  
...  

ObjectivesThe role of faecal haemoglobin as a colorectal cancer screening tool has been demonstrated. However, the association between the faecal haemoglobin concentration and the risk of cardiovascular disease events and deaths is still unclear.DesignCohort study design.SettingPopulation-based organised integrated service screening in Keelung City, TaiwanParticipantsA total of 33 355 healthy individuals aged over 40 years who were free of cardiovascular disease at study entry were followed up.Main outcomes and measuresNewly diagnosed cardiovascular disease events and deaths.ResultsAfter a median follow-up of 2.39 years, a total of 2768 participants developed cardiovascular events, and after a median follow-up of 8.43 years, 317 cases of cardiovascular deaths occurred. The risk of cardiovascular disease increased with baseline faecal haemoglobin in a dose–response manner, yielding a significant elevated risk of cardiovascular disease in parallel with the incremental concentration of faecal haemoglobin (adjusted HRs=1.04, 1.10, 1.40 and 1.23 for faecal haemoglobin concentrations of 1–19, 20–49, 50–99 and ≥100 ng/mL, trend test, p<0.0001, as compared with the reference group with undetectable faecal haemoglobin concentrations). A similar pattern was observed for the risk of cardiovascular disease deaths. In addition, the faecal haemoglobin improved the prediction performance of the model for the risk of cardiovascular diseases; the integrated discrimination improvement was 0.3% (p<0.001) for cardiovascular events and 0.1% (p=0.020) for cardiovascular deaths.ConclusionsOur data support that faecal haemoglobin concentrations may be associated with the risk of cardiovascular diseases. The biological mechanisms underlying the role of faecal haemoglobin as health outcomes should be investigated.


Author(s):  
Mojtaba ZIAEE ◽  
Reza HAJIZADEH ◽  
Arash KHORRAMI ◽  
Nariman SEPEHRVAND ◽  
Saeideh MOMTAZ ◽  
...  

Opiates are the second most prevalent abused illicit substance after cannabis in the world. The latest United Nations Office on Drugs and Crime (UNODC) report estimated 30% increment in opium cultivation worldwide. High prevalence of opium consumption in eastern countries may be due to the high availability and traditional misconceptions. Opium consumption has been linked to hypertension, diabetes mellitus, dyslipidemia, and coronary artery diseases (CAD). In this review, we will review the association between opium use, cardiovascular diseases, and clinical outcomes. The present evidence suggests that chronic opiate consumption may increase the risk of cardiovascular diseases and related mortality.


2020 ◽  
Vol 12 (1) ◽  
pp. 27-37
Author(s):  
Yifei Wang ◽  
Shi Zhou ◽  
Shuai Lei ◽  
Liying Hao ◽  
Deri Sun ◽  
...  

In recent years, there are increasing evidences of epidemiology and clinic which indicate that vitamin D deficiency has relationship with cardiovascular disease. It was found the levels of vitamin D were negatively correlated with cardiovascular events such as hypertension, heart failure, atrial fibrillation and coronary heart disease. This article reviews the connection between cardiovascular diseases and vitamin D, and explains the underlying mechanisms including regulating renin-angiotensin system or endothelial function, inhibition of natriuretic peptide expression or the release of parathyroid hormone, effects on inflammation or obesity, bioenergetics, activation of extracellular Ca2+, inhibition of oxidative stress, and so on. These mechanisms provide novel strategy for the treatment of these cardiovascular diseases.


2021 ◽  
Vol 8 ◽  
Author(s):  
Xinyi Shen ◽  
Lihua Li ◽  
Zhen Sun ◽  
Guangyao Zang ◽  
Lili Zhang ◽  
...  

Cardiovascular diseases (CVDs) are major causes of mortality and morbidity in the modern society. The rupture of atherosclerotic plaque can induce thrombus formation, which is the main cause of acute cardiovascular events. Recently, many studies have demonstrated that there are some relationships between microbiota and atherosclerosis. In this review, we will focus on the effect of the microbiota and the microbe-derived metabolites, including trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs), and lipopolysaccharide (LPS), on the stability of atherosclerotic plaque. Finally, we will conclude with some therapies based on the microbiota and its metabolites.


Kardiologiia ◽  
2021 ◽  
Vol 61 (3) ◽  
pp. 105-114
Author(s):  
E. A. Medvedeva ◽  
N. E. Zvartau ◽  
S. V. Villevalde ◽  
A. N. Yakovlev ◽  
A. E. Solovieva ◽  
...  

The medical community, researchers and healthcare organizers are constantly challenged by comparing key indexes reflecting the effectiveness of cardiovascular care, primarily for the dynamic assessment and implementation of the world's best practices to reduce cardiovascular mortality. The analysis of health care for patients with cardiovascular diseases (CVD) is a complex, multicomponent process, the structure and key tools of which differ from country to country. Using different data sources, methodological and analytical approaches creates certain limitations and barriers to the assessment. In order to update the ideas about the modern coordinate system and tools for assessing cardiovascular care, the authors presented practices for analyzing major indexes in Russia, European countries, and the United States. The review presents sources of statistical data, principles for assessing risk factors, cardiovascular morbidity and mortality, and specific features of monitoring the availability and quality of cardiovascular care.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 1727-1727
Author(s):  
Marta Alonso Fernández de Gatta ◽  
Ana Martín García ◽  
Félix López Cadenas ◽  
Díaz Peláez Elena ◽  
Tamara Jimenez ◽  
...  

Introduction:Cardiovascular disease (CVD) is an important cause of morbimortality in patients with low risk myelodysplastic syndrome (LR-MDS). Up to 70% of patients suffer cardiovascular events and heart disease is the second cause of death in this context. Cardiac damage etiology is complex and multifactorial in this group of patients. Iron overload cardiomyopathy (IOC) due to transfusion dependency is the most well identified factor in this setting, however other circumstances such as vascular aging, cardiac reserve reduction and high cardiac output related to chronic anemia, among others, play an important role in this population. Thus, despite its importance in MDS patients, prognostic cardiovascular predictive factors are not adequately identified, and cardiac monitoring in these patients is not sufficiently stablished. Therefore, our objectives were to determinate the prevalence and characterization of CVD in LR-MDS patients, to analyze their mortality and cardiovascular prognosis and to identify predictors of cardiovascular events or death (combined event, CE) in this setting. Material and methods: A prospective single center study with 36 LR-MDS patients (31 of them in transfusion requirements) was conducted. All patients underwent a complete hematological and cardiological assessment including ECG, cardiac biomarkers (N-terminal pro b-type natriuretic peptide (NT-proBNP) and high-sensitive cardiac T troponine (hs-cTn)) and cardiac magnetic resonance (CMR) with parametric sequences (T1, T2 and T2* mapping) and myocardial deformation by feature tracking (FT). Univariate and multivariate analysis including clinical, analytical and imaging factors for predicting the combined cardiovascular event (heart failure (HF), arrhythmia or ischemic heart disease) and/or all-cause of mortality (CE) was performed by Cox regression. Results:Thirty-six patients with LR-MDS were recruited from 2016 to 2017, with a mean age of 76 ± 10 years, 53% males. Thirty-one patients (84%) were in transfusion dependency (TD). Regarding baseline characteristics for cardiovascular disease most of them (90.9%) had CV risk factors (CVRFs) and 36% suffered of previous heart disease (Baseline characteristics, hematological and cardiac situation at inclusion in table 1). Cardiac assessment revealed high prevalence of structural heart disease, in most of cases previously unknown and significant incidence of CV events during the follow-up. Thus, Cardiac MR detected high prevalence structural heart disease (table 2). As a result of this first cardiac assessment, 15 patients (42%) required modifications in their cardiovascular treatment and most of cases needed to start cardiovascular treatment. After a median follow up of 2.2 years, 35.5% of TD patients suffered the CE, 16% died and 32% presented cardiovascular events: HF 13.9%, pacemaker implantation due to atrioventricular block 2.8%, ischemic heart disease 5.6%, and atrial fibrillation 5.6%. In the univariate analysis for the CE (table 3), higher hs-cTn (p=0,007), higher NT-proBNP (p = 0.001), T2* <20 ms (p = 0.008), lower T1 native time (p = 0.048) and higher longitudinal strain (p=0,047) were all significant negative prognostic factors for developing CE. NT-proBNP value higher than 485pg/ml (HR 96,7; IC 95% 1,135-8243; p = 0,044), native T1 time lower than 983 ms (HR 44,8; IC 95% 1,235-1623; p = 0,038) and higher LS (p=0,043) retained its independent adverse prognostic factor in the multivariate analysis for CE. Conclusion: LR- MDS patients presented high prevalence of cardiovascular risk factors and structural heart disease and most of cases were only identified after an appropriate cardiological assessment. The presence of a CV event and/or death is very frequent during patients follow up. Cardiac biomarkers and CMR could improve the identification of patients at risk for CVD in which a cardiological treatment and follow-up could improve survival. Disclosures Díez-Campelo: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.


Sign in / Sign up

Export Citation Format

Share Document